

The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment)

https://marketpublishers.com/r/MC76A94DC06EN.html

Date: August 2013

Pages: 230

Price: US\$ 3,995.00 (Single User License)

ID: MC76A94DC06EN

Abstracts

Given the cost of hospital-acquired and healthcare-associated infections (HAIs), demand has increased for solutions that can help the healthcare industry reduce infections and the costs associated with them. The U.S. Centers for Disease Control and Prevention (CDC) estimates that around 1 in 20 or 5% of hospitalized patients will contract an HAI. Worldwide, the rate of nosocomial infections is between 3.5% and 12% of admissions in developed regions. This has created a market opportunity for companies that can test for, treat and help prevent these infections. This opportunity is detailed in Kalorama Information's report, The Market for Hospital-Acquired Infection Control (Sterilization, Cleaning, Testing, Treatment)

This report focuses on preventing, testing and treating infections in the healthcare environment. The major consideration is given to bacterial nosocomial infections because a) they are the most frequent type of infections spread in the health care delivery setting, and b) the practical aspects of diagnosis and therapy are more meaningful based on a combination of medical and financial considerations.

The report will provide a market analysis in the areas of Prevention, Testing and Treatment.

Market analysis in this report considers primarily the epidemiological considerations and the size patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis.

Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic



and therapeutic products). In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital and primary care environment in order to construct a picture of the infection prevention, testing and treatment needs.

In looking at infections in the health environment, we consider the diagnostic and therapeutic technologies that are currently available and attempt to project trends for preventing, detecting and treating these infections. To some extent, we are limited by the activity of the industries associated with the activities mentioned above for these infections. For the most part, these activities are limited and the advanced technologies seen in other areas of medical application are not necessarily present in terms of microbiology.

The majority of competitive participation for Hospital-Acquired Infection control and is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. Companies in this report include:

Advanced Sterilization Products
Becton Dickinson
Belimed AG
bioMerieux
Cantel
Cepheid
Kimberly-Clark
Merck & Co.
Nordion
Pfizer

Roche



Steris

TSO3



Contents

CHAPTER ONE: EXECUTIVE SUMMARY

Overview

The Nosocomial Infection
Scope and Methodology
Total Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

Overview

Introduction to Pathogens

Classification of Antibacterial Organisms

Patient Risk Factors

General Infection Statistics

Populations at Risk for Infection

Demographics of the World

Life Expectancy

Nosocomial Infection Statistics

Common Hospital (nosocomial) Infections

Description of Infections

Infection Risk Assessments by Hospital Department

Burn Units

Intensive Care Units

Emergency Departments

Hospital Length of Stay

Extended Stay Environments

International Trends in Nursing Facilities

Economic Trends

Comparison Between Healthcare Spending and Real Health Outcomes

U.S. Government's National Plan to Prevent Healthcare Associated Infections (HAIs)

Steering Committee

The American Recovery and Reinvestment Act of 2009

Affordable Care Act (ACA) Funding

Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Funding

U.S. Statewide Standardized Infection Ratio



Reduction in Hospital Acquired Infections

Reduction in Infections in Israel

Burden of Hospital Acquired Infections

Hospital-Acquired Infection Surveillance Process

Case Studies

Arizona Prevention Study

Connecticut Funding for HAI Prevention and Reporting

Pennsylvania Study of HAI Admissions and Readmissions

Infections and Drug Resistance

Easing Approvals of Antibiotics

Causes of Drug Resistance

Antibiotic Abuse

Antibiotic Use in Agriculture

Drug Resistance in Select Populations

Children

The Elderly

Compromised Individuals

Measures for Reducing Resistance

Testing for the Selection of Anti-bacterial Therapy

Monitoring Therapy

Screening Hospitalized patients

Pharmaceutical Manufacturer and Marketer Trends

Trends in Partnerships and Alliances

Developers Trends

CHAPTER THREE: INFECTION PREVENTION

Overview

Methods of Transmission

Airborne

Contact

Droplet

Vehicle

High-Risk Facilities or Departments

Technology Overview

Potential Use of Copper for Reducing Infections

Wide Area Disinfection Methods

Software for Infection Detection and Control

Antiseptic-Coated Catheters



Sterilization vs. Disinfection

Sterilization

Disinfection

Equipment and Solutions

Heat/Steam Sterilization

Developments

Chemical Sterilization

Sterilants

Developments

Radiation Sterilization

Developments

Market Overview

Hospital-Acquired Infection Prevention Market by Geographical Region

Competitive Analysis

CHAPTER FOUR: INFECTION TESTING

Overview

Drug-Resistance/Susceptibility Testing

Genotypic Methods

DNA Sequencing

Solid-phase Hybridization Techniques

Microarrays

Real-time Polymerase Chain Reaction Techniques

Phenotypic Methods

Phage-based Assays

Colorimetric Methods

The Nitrate Reductase Assay

Specific Serious Hospital-Acquired Infection Testing

Acinetobacter Baumannii

Clostridium Difficile

Developments

Hospital-Acquired Pneumonia

Pseudomonas Aeruginosa

Staphylococcus Aureus

Methicillin-resistant Staphylococcus Aureus (MRSA)

Vancomycin-Intermediate/Resistant Staphylococcus Aureus (VISA/VRSA)

Developments

Tuberculosis



Developments

Urinary Tract Infections

Vancomycin-resistant Enterococcus

Developments

Ventilator-Associated Pneumonia

New Developments

Market Overview

Total Market Size and Forecast

Hospital-Acquired Infection Testing Market by Geographical Region

Competitive Analysis

CHAPTER FIVE: INFECTION TREATMENT

Overview

Principles of Anti-bacterial Therapy

Infecting Organism

Antibiotic Sensitivity Testing

Site of Infection

Host Defenses and Organ Function

Antibiotic Pharmacokinetics

Monitoring Therapy

Classifications of Antibacterial Products

Carbapenems

Cephalosporins

Macrolides

Penicillins

Quinolones

Sulfonamides

Tetracyclines

Treatment Guidelines

Clostridium Difficile

Gastroenteritis

Hospital-Acquired Pneumonia

Ventilator-associated Pneumonia

Pseudomonas Aeruginosa

Staphylococcus Aureus

Stenotrophomonas maltophilia

Tuberculosis

Urinary Tract Infections



Leading Products

New Developments

Total Market Size and Forecast

Hospital-Acquired Infection Treatment Market by Geographical Region

Competitive Analysis

CHAPTER SIX: MARKET OPPORTUNITIES FOR HOSPITAL-ACQUIRED INFECTION CONTROL

Market Considerations

Market Overview

Hospital-Acquired Infection Control Market by Geographical Region

CHAPTER SEVEN: COMPANY PROFILES

Introduction

Advanced Sterilization Products

Company Performance

Becton, Dickinson

Company Performance

Belimed

Company Performance

bioMerieux

Company Performance

Cantel

Company Performance

Cepheid

Company Performance

Getinge Group

Company Performance

Kimberly-Clark

Company Performance

Merck & Co

Company Performance

Nordion

Company Performance

Pfizer

Company Performance

Roche



Company Performance Sakura Seiki Steris Company Performance Tso3 Company Performance

LIST OF MAJOR PROVIDERS



About

Gastroenteritis

Gastroenteritis is a condition that causes irritation and inflammation of the stomach and intestines of the gastrointestinal tract. Diarrhea, crampy abdominal pain, nausea, and vomiting are the most common symptoms. Viral infection is the most common cause of gastroenteritis but bacteria, parasites, and food-borne illness (such as shellfish) can be the offending agent. Nosocomial gastroenteritis can be caused by bacteria or viruses (most frequently, viruses).

Bacterial causes of gastro enteritis include infection with:
Staphylococcus aureus
E. coli
Salmonella
Shigella
Campylobacter
C. difficile

Classifications of Antibacterial Products

Several classifications of antibacterials are available for treating infections:

Carbapenems
Cephalosporins
Macrolides

Penicillins



_						
O	:		_	۱.		
()		n	O	m	n	$\neg c$

Sulfonamides

Tetracyclines



I would like to order

Product name: The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and

Treatment)

Product link: https://marketpublishers.com/r/MC76A94DC06EN.html

Price: US\$ 3,995.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/MC76A94DC06EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



